Drugs / Vancomycin
Vancomycin
also known as
vancomycin hydrochloride · Oral vancomycin · VAN · Vancomycin HCl · Vancomycine · Firvanq · Firvanq kit · Novaplus · +24 more
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | TYZAVAN | — | 2021-05-28 – 2025-06-27 | fda.gov ↗ |
| Label expansion | US (FDA) | VANCOMYCIN HYDROCHLORIDE | — | 2024-06-26 | fda.gov ↗ |
| Label expansion | US (FDA) | VANCOCIN HYDROCHLORIDE | — | 2011-12-14 | fda.gov ↗ |
| Label expansion | US (FDA) | VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER | — | 1998-01-08 | fda.gov ↗ |
| Approved | US (FDA) | VANCOCIN HYDROCHLORIDE | — | 1964-11-06 | fda.gov ↗ |
Trials 207 · started per year
today
US approved 1964
1
1
2
3
2
2
3
3
3
1
1
3
6
14
11
12
10
9
7
11
14
8
13
13
14
12
10
16
1963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
Also used as a comparator or background therapy in 236 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 06 trials | ||||||
| Phase 0 | NCT05829109 Background | Sep 2024 → Dec 2026 expected | pouchitis | Maia Kayal | Recruiting | No outcome recorded |
| Phase 0 | NCT06197308 Background | Mar 2024 → Mar 2027 expected | primary sclerosing cholangitis | University of Minnesota | Recruiting | No outcome recorded |
| Phase 0 | NCT04968951 Comparator | Nov 2021 → Aug 2022 | ulcerative colitis | Ari M Grinspan | Terminated | No outcome recorded |
| Phase 0 | NCT06967376 Comparator | May 2018 → Nov 2021 | keratitis | Research Institute of Ophthalmology, Egypt | Completed | No outcome recorded |
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 0 | NCT01731236 Comparator | Feb 2011 → Dec 2027 expected | — | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase 115 trials | ||||||
| Phase 1 | NCT06647277 Background | Jul 2026 → Dec 2027 expected | Parkinson disease | ProgenaBiome | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07490054 Background | Sep 2025 → Sep 2027 expected | heart failure | Melana Yuzefpolskaya, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT06582264 Background | Sep 2024 → Jan 2026 | ulcerative colitis | Microbiotica Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06540391 Background | Aug 2024 → Dec 2025 overdue | melanoma | Microbiotica Ltd | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05693077 Background | Sep 2023 → Jun 2024 | Clostridium infectious disease | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT04948814 Background | Jun 2022 → Jun 2024 | autism spectrum disorder | Tongji Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04995653 Background | Nov 2021 → Jul 2024 | disease related to hematopoietic stem cell transplant | Seres Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06030219 Comparator | Oct 2020 → Sep 2023 | — | University of Houston | Completed | No outcome recorded |
| Phase 1 | NCT03827447 Comparator | Jul 2019 → Jun 2021 | Clostridium difficile colitis | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 1 | NCT03817125 Background | Jan 2019 → Mar 2022 | metastatic melanoma | Parker Institute for Cancer Immunotherapy | Completed | No outcome recorded |
| Phase 1 | NCT03403972 Background | Dec 2017 → Jan 2018 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04236778 Background | Nov 2017 → Mar 2019 | — | Vedanta Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02865616 Background | Oct 2017 → Mar 2020 | Clostridium infectious disease | NuBiyota | Completed | No outcome recorded |
| Phase 1 | NCT01764750 Comparator | Jan → Dec 2013 | necrotizing soft tissue infection | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT00925093 Comparator | Sep 2011 → Dec 2012 | — | Aarhus University Hospital | Withdrawn | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07031999 Background | Jun 2026 → Aug 2028 expected | infectious disease | Hospital Universitario Evangelico de Curitiba | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05576961 Background | Sep 2022 → Dec 2024 | cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04208958 Background | Jan 2020 → Aug 2021 | colorectal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, melanoma +1 | Vedanta Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03466645 Comparator | Apr 2018 → Apr 2019 | — | Isfahan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT02504554 Background | Jul 2014 → Apr 2016 | autism spectrum disorder, digestive system disorder | Arizona State University | Completed | No outcome recorded |
| Phase 248 trials | ||||||
| Phase 2 | NCT07201987 Background | Jan 2027 → Jan 2028 expected | — | Ganesh M. Shankar | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06428448 Background | Feb 2026 → Aug 2027 expected | periprosthetic joint infection | OsteoRemedies, LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT07207434 Comparator | Aug 2025 → Aug 2026 overdue | — | Aga Khan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07134790 Comparator | Jul 2025 → Jul 2026 overdue | — | University Ghent | Recruiting | No outcome recorded |
| Phase 2 | NCT05690048 Background | Jul 2025 → Mar 2028 expected | hepatocellular carcinoma | Michael Dill | Recruiting | No outcome recorded |
| Phase 2 | NCT06817031 Comparator | Apr 2025 → Apr 2026 overdue | — | International Centre for Diarrhoeal Disease Research, Bangladesh | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06716749 Background | Dec 2024 → May 2025 | osteoarthritis, knee | Carilion Clinic | Completed | No outcome recorded |
| Phase 2 | NCT05370885 Background | May 2023 → Aug 2025 | ulcerative colitis | Vedanta Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03617445 Comparator | Aug 2022 → Jun 2023 | Clostridium difficile colitis | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 2 | NCT04983901 Background | Sep 2021 → Oct 2023 | cancer, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT04899115 Background | Aug 2021 → Apr 2023 | cirrhosis of liver, hepatic encephalopathy | Patricia Bloom | Completed | No outcome recorded |
| Phase 2 | NCT04775953 Comparator | Apr 2021 → Oct 2023 | staphylococcal infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04729322 Background | Feb 2021 → Dec 2027 expected | colorectal adenocarcinoma, small intestine adenocarcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04781387 Comparator | Jan 2021 → Apr 2024 | Clostridium infectious disease | Crestone, Inc | Completed | No outcome recorded |
| Phase 2 | NCT04247542 Comparator | Mar 2020 → Oct 2023 | Clostridium infectious disease | Acurx Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04238091 Comparator | Dec 2019 → Mar 2022 | alopecia areata, alopecia totalis, alopecia universalis | Lindsey Bordone | Withdrawn | No outcome recorded |
| Phase 2 | NCT04017468 Comparator | Oct 2019 → Sep 2026 expected | — | Insel Gruppe AG, University Hospital Bern | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03964493 Comparator | Apr 2019 → Sep 2020 | gram-positive bacterial infections, skin disease caused by bacterial infection | TenNor Therapeutics Limited | Completed | No outcome recorded |
| Phase 2 | NCT03759041 Background | Dec 2018 → May 2021 | ulcerative colitis | Seres Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03476317 Background | Jul 2018 → Dec 2020 | Crohn disease | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 2 | NCT03030248 Comparator | Jun 2018 → Jun 2020 | Clostridium difficile colitis, cancer-related condition, hematologic disorder | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 2 | NCT03452189 Comparator | Nov 2017 → Aug 2018 | end stage renal failure | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT02765256 Background | Aug 2016 → Dec 2018 | Crohn disease | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT02732327 Background | May → Jun 2016 | neoplasm, neutropenia | Forest Laboratories | Terminated | No outcome recorded |
| Phase 2 | NCT02641236 Comparator | Mar 2016 → Apr 2021 | acute graft versus host disease | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT03427229 Background | Mar 2016 → Oct 2017 | Clostridium difficile colitis | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| Phase 2 | NCT02426918 Comparator | May 2015 → Aug 2016 | bacterial infectious disease | Debiopharm International SA | Completed | No outcome recorded |
| Phase 2 | NCT02301221 Background | Mar 2015 → Mar 2016 | intestinal dysmotility syndrome | Jinling Hospital, China | Unknown | No outcome recorded |
| Phase 2 | NCT02857582 Comparator | Oct 2014 → Oct 2018 | Clostridium difficile colitis | Per Hellström | Completed | No outcome recorded |
| Phase 2 | NCT02092935 Comparator | Apr 2014 → Oct 2015 | Clostridium difficile colitis | Summit Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02168816 Comparator | Mar 2014 → Feb 2017 | osteomyelitis | Loyola University | Terminated | No outcome recorded |
| Phase 2 | NCT01975662 Comparator | Jan 2014 → Dec 2015 | staphylococcus aureus infection | Singapore General Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01756924 Comparator | Dec 2012 → Jul 2014 | periprosthetic joint infection | Arrevus Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01757236 Background | Oct 2012 → Apr 2016 | periprosthetic joint infection | University Hospital, Tours | Unknown | No outcome recorded |
| Phase 2 | NCT01191840 Comparator | Feb 2011 → Mar 2017 | bacterial infectious disease | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT01222702 Comparator | Jan 2011 → Oct 2012 | Clostridium difficile colitis | Actelion | Completed | No outcome recorded |
| Phase 2 | NCT01283581 Comparator | Jan → Nov 2011 | skin disease caused by bacterial infection | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01232595 Comparator | Oct 2010 → Jul 2013 | Clostridium difficile colitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01570192 Background | Sep 2010 → Apr 2015 | bacterial pneumonia | University of Florida | Terminated | No outcome recorded |
| Phase 2 | NCT01119105 Comparator | May → Dec 2010 | bacterial infectious disease, skin infection | Nabriva Therapeutics AG | Completed | No outcome recorded |
| Phase 2 | NCT01085591 Comparator | Apr 2010 → Apr 2011 | Clostridium difficile colitis, diarrheal disease | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00543608 Comparator | Nov 2007 → Apr 2009 | nosocomial infection | Arpida AG | Terminated | No outcome recorded |
| Phase 2 | NCT00428844 Comparator | Jun 2007 → Mar 2010 | osteomyelitis | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00442832 Comparator | Dec 2006 → May 2007 | staphylococcal infection | Theravance Biopharma | Completed | No outcome recorded |
| Phase 2 | NCT00303589 Comparator | Dec 2005 → Oct 2007 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00077675 Comparator | Feb → Sep 2004 | gram-positive bacterial infections | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00062647 Comparator | Aug 2003 → Aug 2006 | gram-positive bacterial infections | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00061633 Comparator | Jun 2003 → Jan 2004 | abscess, cellulitis, gram-positive bacterial infections, ulcer disease | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT07221370 Comparator | Oct 2024 → Dec 2026 expected | Clostridium difficile colitis, Enterococcus infectious disease | Riverside University Health System Medical Center | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03105479 Comparator | Apr 2017 → Apr 2018 | Clostridium difficile colitis | Actelion | Terminated | No outcome recorded |
| Phase 2/3 | NCT02686645 Background | Dec 2016 → Dec 2021 | Clostridium difficile colitis | Queen Elizabeth II Health Sciences Centre | Unknown | No outcome recorded |
| Phase 2/3 | NCT02466698 Background | Aug 2016 → Aug 2019 | Clostridium difficile colitis | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 2/3 | NCT02191475 Comparator | May 2014 → May 2017 | digestive system infectious disorder | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT01400867 Comparator | Dec 2011 → May 2014 | primary bacterial infectious disease | Forest Laboratories | Completed | No outcome recorded |
| Phase 2/3 | NCT01226992 Comparator | Oct 2010 → Oct 2014 | Clostridium difficile colitis | University Health Network, Toronto | Terminated | No outcome recorded |
| Phase 364 trials | ||||||
| Phase 3 | NCT07435051 Comparator | May 2026 → Dec 2029 expected | osteomyelitis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07107477 Comparator | May 2025 → Sep 2027 expected | preterm premature rupture of the membranes | The Central and Eastern European Gynecologic Oncology Group | Recruiting | No outcome recorded |
| Phase 3 | NCT06443502 Background | Nov 2024 → Dec 2029 expected | pouchitis | Takeda | Recruiting | No outcome recorded |
| Phase 3 | NCT06336824 Comparator | Jun 2024 → May 2025 overdue | staphylococcus aureus infection | Clinical Research Centre, Malaysia | Recruiting | No outcome recorded |
| Phase 3 | NCT06107569 Comparator | May 2024 → Dec 2025 | Clostridium difficile colitis | Hospital Universitario Evangelico de Curitiba | Unknown | No outcome recorded |
| Phase 3 | NCT05266807 Background | Mar 2023 → Apr 2027 expected | Clostridium difficile colitis | Benoit Guery | Recruiting | No outcome recorded |
| Phase 3 | NCT04802837 Comparator | May → Sep 2021 | Clostridium infectious disease | Summit Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT04597008 Comparator | May 2021 → Jul 2025 | — | Major Extremity Trauma Research Consortium | Completed | No outcome recorded |
| Phase 3 | NCT02801656 Comparator | Dec 2020 → Sep 2022 | Clostridium difficile colitis | Memorial University of Newfoundland | Withdrawn | No outcome recorded |
| Phase 3 | NCT04138706 Comparator | Nov 2020 → Oct 2024 | Clostridium difficile colitis | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 3 | NCT04042077 Comparator | Sep 2019 → Oct 2020 | — | Menarini Group | Terminated | No outcome recorded |
| Phase 3 | NCT03796650 Comparator | Jul 2019 → Apr 2024 | Clostridium difficile colitis | Oslo University Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT03595553 Comparator | Jan 2019 → Nov 2021 | Clostridium infectious disease | Summit Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03176134 Comparator | Jan 2019 → Jul 2023 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03182907 Background | Mar 2018 → May 2022 | Clostridium difficile colitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03137173 Comparator | Feb 2018 → Apr 2019 | — | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 3 | NCT03439124 Comparator | Nov 2017 → Mar 2020 | bacterial pneumonia | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 3 | NCT02814916 Comparator | Mar 2017 → Jan 2024 | methicillin-resistant staphylococcus aureus infectious disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02743234 Comparator | Apr 2016 → Feb 2019 | Clostridium difficile colitis | University of Aarhus | Completed | No outcome recorded |
| Phase 3 | NCT02344511 Comparator | Mar 2016 → Oct 2018 | osteomyelitis | Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) | Withdrawn | No outcome recorded |
| Phase 3 | NCT02600611 Comparator | Nov 2015 → Jan 2017 | — | Motif Bio | Completed | No outcome recorded |
| Phase 3 | NCT02607618 Comparator | Nov 2015 → Aug 2017 | — | Motif Bio | Completed | No outcome recorded |
| Phase 3 | NCT02276482 Comparator | Mar 2015 → Sep 2018 | skin disease caused by bacterial infection, skin infection | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02218372 Comparator | Jan 2015 → Mar 2018 | Clostridium difficile colitis | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 3 | NCT02208063 Comparator | Dec 2014 → Apr 2018 | bacterial infectious disease | Cumberland Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT02179658 Comparator | Jun 2014 → Sep 2016 | Clostridium difficile colitis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT02202135 Comparator | Jun 2014 → Jan 2015 | — | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT01984684 Comparator | May 2014 → Dec 2015 | skin disease caused by bacterial infection | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01987895 Comparator | Mar 2014 → Feb 2017 | Clostridium infectious disease | Actelion | Completed | No outcome recorded |
| Phase 3 | NCT01922011 Comparator | Sep 2013 → Jun 2016 | osteomyelitis | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01811732 Comparator | Apr 2013 → Jul 2014 | skin disease caused by bacterial infection | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01598311 Comparator | May 2012 → Jul 2015 | Clostridium difficile colitis | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01597505 Comparator | May 2012 → Mar 2015 | Clostridium difficile colitis | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01499277 Comparator | May 2012 → Jun 2014 | necrotizing soft tissue infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01515020 Comparator | May 2012 → Jun 2013 | nosocomial infection | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 3 | NCT01513239 Background | Feb 2012 → May 2015 | Clostridium difficile colitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01241552 Background | Oct 2011 → Dec 2014 | Clostridium difficile colitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00911573 Comparator | Aug 2011 → May 2014 | infectious disease, skin disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Withdrawn | No outcome recorded |
| Phase 3 | NCT01431339 Comparator | Jul 2011 → Nov 2012 | abscess, cellulitis, skin infection | Durata Therapeutics Inc., an affiliate of Allergan plc | Completed | No outcome recorded |
| Phase 3 | NCT01199783 Comparator | Jul 2011 → Oct 2013 | — | Ruhr University of Bochum | Terminated | No outcome recorded |
| Phase 3 | NCT01339091 Comparator | Mar 2011 → Sep 2012 | abscess, cellulitis, skin infection | Durata Therapeutics Inc., an affiliate of Allergan plc | Completed | No outcome recorded |
| Phase 3 | NCT01252719 Comparator | Dec 2010 → Oct 2012 | abscess, cellulitis, skin infection | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01252732 Comparator | Dec 2010 → Jun 2013 | abscess, cellulitis, skin infection | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01184872 Comparator | Mar 2010 → Mar 2011 | skin infection | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00772447 Comparator | Sep 2008 → Sep 2010 | infectious disease, skin disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00770341 Comparator | Sep 2008 → Feb 2010 | staphylococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00529282 Comparator | Oct 2007 → Jan 2008 | Pseudomonas infection, gram-positive bacterial infections, neutropenia | Basilea Pharmaceutica | Terminated | No outcome recorded |
| Phase 3 | NCT00427076 Comparator | Jun 2007 → May 2014 | infectious disease with sepsis, meningitis, pneumonia, staphylococcal infection | Rabin Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01867138 Comparator | Mar 2007 → Aug 2010 | neonatal sepsis | Hospital Italiano de Buenos Aires | Completed | No outcome recorded |
| Phase 3 | NCT00423657 Comparator | Mar → Dec 2007 | bacterial infectious disease | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00424190 Comparator | Feb → Nov 2007 | bacterial infectious disease | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00384527 Comparator | Dec 2006 → Oct 2007 | Clostridium infectious disease | Romark Laboratories L.C. | Terminated | No outcome recorded |
| Phase 3 | NCT00468728 Comparator | Oct 2006 → Dec 2009 | Clostridium difficile colitis, diarrheal disease | Optimer Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 3 | NCT00314951 Comparator | May 2006 → Jul 2008 | Clostridium infectious disease, diarrheal disease | Optimer Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 3 | NCT00324922 Comparator | May 2006 → May 2007 | methicillin-resistant staphylococcus aureus infectious disease, osteomyelitis | University of Washington | Completed | No outcome recorded |
| Phase 3 | NCT00430937 Comparator | Apr 2006 → Mar 2008 | skin infection | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00269399 Comparator | Dec 2005 → Dec 2008 | Clostridium difficile colitis, diarrheal disease | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00210899 Comparator | Sep 2005 → Oct 2006 | skin disease caused by bacterial infection, staphylococcal infection | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 3 | NCT00107952 Comparator | Feb 2005 → Jul 2007 | bacterial pneumonia | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00107978 Comparator | Feb 2005 → May 2006 | staphylococcal infection | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00091819 Comparator | Jan 2005 → Jun 2006 | staphylococcal infection | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00124020 Comparator | Jan 2005 → May 2007 | bacterial pneumonia | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00228982 Comparator | Oct 2004 → Dec 2005 | skin disease caused by bacterial infection, skin infection, staphylococcal infection | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 3 | NCT00050401 Background | Jul 2002 → Sep 2004 | pneumonia | Pfizer | Completed | No outcome recorded |
| Phase 462 trials | ||||||
| Phase 4 | NCT06794944 Comparator | Sep 2026 → Sep 2030 expected | Clostridium difficile colitis | Brigham and Women's Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07590648 Background | Jun 2026 → Jul 2028 expected | bacterial infectious disease, childhood malignant neoplasm, hematopoietic and lymphoid cell neoplasm, neutropenia | Hospital Universitari Vall d'Hebron Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06954129 Comparator | Jan 2026 → May 2029 expected | acute kidney injury | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 4 | NCT07148960 Comparator | Sep 2025 → Jul 2027 expected | staphylococcus aureus infection | West Virginia University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07072923 Comparator | Sep 2025 → Jul 2027 expected | osteomyelitis | University of Arizona | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06384651 Comparator | Dec 2024 → Apr 2027 expected | arthropathy, infectious disease | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT06637332 Comparator | Nov 2024 → Jan 2027 expected | bacterial infectious disease with sepsis, infective endocarditis, staphylococcus aureus infection | Todd C. Lee MD MPH FIDSA | Recruiting | No outcome recorded |
| Phase 4 | NCT05571722 Comparator | Nov 2024 → Dec 2028 expected | — | Assistance Publique Hopitaux De Marseille | Recruiting | No outcome recorded |
| Phase 4 | NCT06814223 Comparator | Oct 2024 → Dec 2027 expected | prosthesis-related infectious disease | Western Galilee Hospital-Nahariya | Recruiting | No outcome recorded |
| Phase 4 | NCT04401553 Comparator | Aug 2024 → Aug 2026 | drug pseudoallergy | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT05977868 Comparator | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT05971537 Comparator | Jun 2023 → Oct 2026 expected | infectious peritonitis | Alice Ho Miu Ling Nethersole Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05823116 Comparator | May 2023 → Jun 2025 | — | Aaron Cook | Completed | No outcome recorded |
| Phase 4 | NCT05421741 Comparator | May 2023 → Dec 2026 expected | osteomyelitis | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT04825522 Comparator | Mar 2022 → Dec 2028 expected | vertebral column disorder | Windsor-Essex Compassionate Care Community | Recruiting | No outcome recorded |
| Phase 4 | NCT05077085 Background | Jan 2022 → Jul 2024 | Clostridium difficile colitis, Clostridium infectious disease | Leiden University Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT04917627 Comparator | May 2021 → May 2022 | skin infection | Hamad General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04648696 Comparator | Mar 2021 → Oct 2022 | infectious disease | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 4 | NCT04241744 Comparator | Oct 2019 → Jan 2020 | CADINS disease | Creighton University | Withdrawn | No outcome recorded |
| Phase 4 | NCT03880539 Background | Jun 2019 → Nov 2021 | Clostridium difficile colitis | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03557008 Comparator | Jul 2018 → Jun 2022 | rabies | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT03432858 Comparator | May 2018 → Dec 2020 | carpal tunnel syndrome | WellSpan Health | Completed | No outcome recorded |
| Phase 4 | NCT03438214 Comparator | Apr 2018 → Feb 2020 | gram-positive bacterial infections, infectious disease with sepsis, poisoning | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT03402945 Comparator | Mar 2018 → Apr 2023 | — | Population Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT03426761 Comparator | Jan 2018 → Dec 2022 | osteomyelitis, periprosthetic joint infection | Infectious Diseases Physicians, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT03388268 Comparator | Dec 2017 → Jan 2021 | Clostridium difficile colitis, diarrheal disease | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03273296 Comparator | Oct → Dec 2017 | — | Finnish Institute for Health and Welfare | Completed | No outcome recorded |
| Phase 4 | NCT02692651 Comparator | May 2017 → May 2021 | Clostridium difficile colitis | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT02996487 Comparator | Dec 2016 → Jun 2023 | Clostridium difficile colitis | Corewell Health East | Completed | No outcome recorded |
| Phase 4 | NCT02660346 Comparator | Nov 2015 → Sep 2017 | bacterial infectious disease | Sharp HealthCare | Completed | No outcome recorded |
| Phase 4 | NCT02819908 Comparator | Sep 2015 → Apr 2016 | uveal disorder | Eye Center of North Florida | Completed | No outcome recorded |
| Phase 4 | NCT02463747 Background | Jun 2015 → Jun 2017 | neutropenia | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02384200 Background | Mar 2015 → Feb 2017 | nephrolithiasis, urinary tract infection | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT02515045 Comparator | Jan 2015 → Mar 2016 | cataract | Carolina Eyecare Physicians, LLC | Completed | No outcome recorded |
| Phase 4 | NCT02307006 Comparator | Jan 2015 → Dec 2016 | — | University of Cincinnati | Unknown | No outcome recorded |
| Phase 4 | NCT02057198 Comparator | Jun 2014 → Jun 2017 | Clostridium difficile colitis, diarrheal disease, enterocolitis | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT02355938 Comparator | Feb 2014 → Oct 2016 | Clostridium difficile colitis, spinal cord injury | Baylor College of Medicine | Terminated | No outcome recorded |
| Phase 4 | NCT01977989 Comparator | Oct 2013 → Oct 2015 | skin infection | University of Tennessee | Unknown | No outcome recorded |
| Phase 4 | NCT01775397 Comparator | Nov 2012 → Apr 2013 | Clostridium difficile colitis | Astellas Pharma Europe Ltd. | Terminated | No outcome recorded |
| Phase 4 | NCT01728376 Comparator | Nov 2012 → Jan 2016 | bacterial infectious disease | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01818141 Comparator | Oct 2012 → Dec 2014 | Clostridium difficile colitis | Hartford Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01669980 Comparator | Oct 2012 → May 2014 | pneumonia | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT01645735 Comparator | Oct 2012 → Dec 2013 | respiratory tract infectious disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT01549613 Comparator | May 2012 → Jul 2013 | cellulitis, skin infection | University of Cincinnati | Completed | No outcome recorded |
| Phase 4 | NCT01619982 Comparator | Feb 2012 → Dec 2014 | aortic valve disorder, congenital heart disease | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT02582203 Comparator | Feb 2012 → May 2016 | skin disorder caused by infection, staphylococcal infection | Wayne State University | Completed | No outcome recorded |
| Phase 4 | NCT01734694 Comparator | Oct 2011 → Sep 2012 | bacterial infectious disease, endocarditis, nosocomial infection, osteomyelitis | Henry Ford Health System | Terminated | No outcome recorded |
| Phase 4 | NCT01419184 Comparator | Sep 2011 → Sep 2012 | staphylococcus aureus infection | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01287832 Comparator | Jun 2011 → Jan 2012 | bacterial infectious disease | St. John Health System, Michigan | Terminated | No outcome recorded |
| Phase 4 | NCT01613092 Comparator | May 2011 → Nov 2013 | cardiac rhythm disease | Population Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01612052 Comparator | May 2011 → Mar 2013 | methicillin-resistant staphylococcus aureus infectious disease | CAMC Health System | Unknown | No outcome recorded |
| Phase 4 | NCT01196169 Comparator | Oct 2010 → Mar 2014 | methicillin-resistant staphylococcus aureus infectious disease | Mountain Home Research & Education Corporation | Terminated | No outcome recorded |
| Phase 4 | NCT01133600 Comparator | Aug 2010 → Aug 2012 | — | Clinical Alliance for Research & Education - Infectious Diseases, LLC. | Terminated | No outcome recorded |
| Phase 4 | NCT01175707 Comparator | Jul 2010 → Nov 2011 | — | Merck & Co., Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT01104662 Comparator | Apr 2010 → Jun 2012 | impaired renal function disease, staphylococcus aureus infection | Merck & Co., Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00871104 Comparator | Jul 2009 → Jul 2014 | infective endocarditis | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase 4 | NCT00711802 Comparator | Jul 2008 → Oct 2013 | skin disease caused by bacterial infection | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00634166 Background | Sep 2007 → Dec 2013 | — | Mylan Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00423982 Comparator | Apr 2006 → Dec 2012 | periprosthetic joint infection, staphylococcal infection | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00304811 Background | Jan 2006 → Jan 2007 | staphylococcus aureus infection | Michael E. DeBakey VA Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00454272 Comparator | Jan 2005 → Aug 2007 | infectious disease, neutropenia | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00084266 Comparator | Oct 2004 → Mar 2010 | methicillin-resistant staphylococcus aureus infectious disease | Pfizer | Completed | No outcome recorded |
| Phase not applicable29 trials | ||||||
| — | NCT07495150 Background | Apr 2026 → Apr 2027 expected | bacterial meningitis | yilong Wang | Not yet recruiting | No outcome recorded |
| — | NCT07013552 Comparator | Jun 2025 → Jul 2026 overdue | gram-positive bacterial infections, infective endocarditis, nosocomial infection, prosthesis-related infectious disease | Medical University of Silesia | Not yet recruiting | No outcome recorded |
| — | NCT06439953 Comparator | Oct 2024 → Sep 2026 expected | infectious disease | Rhode Island Hospital | Recruiting | No outcome recorded |
| — | NCT06527131 Comparator | Jul → Oct 2024 overdue | ulcer of lower limbs | Cairo University | Recruiting | No outcome recorded |
| — | NCT06084754 Background | Nov → Dec 2023 | osteomyelitis | Cairo University | Unknown | No outcome recorded |
| — | NCT05709184 Comparator | Nov 2023 → Nov 2025 | Clostridium infectious disease | Rambam Health Care Campus | Unknown | No outcome recorded |
| — | NCT05651464 Comparator | Jan → Dec 2023 | prosthesis-related infectious disease | Saarland University | Unknown | No outcome recorded |
| — | NCT03939273 Comparator | Mar 2022 → Mar 2023 | autoinflammatory syndrome, coronary artery disorder | Radboud University Medical Center | Unknown | No outcome recorded |
| — | NCT03839914 Comparator | Aug 2020 → Mar 2027 expected | scoliosis, spinal cord neoplasm | The University of Hong Kong | Active not recruiting | No outcome recorded |
| — | NCT04297176 Comparator | Jan 2020 → May 2021 | bacterial infectious disease | Hamad Medical Corporation | Completed | No outcome recorded |
| — | NCT04048304 Background | Jul 2019 → Feb 2025 overdue | infectious disease | Balgrist University Hospital | Recruiting | No outcome recorded |
| — | NCT03053505 Comparator | Jan → Dec 2017 | Clostridium infectious disease | Sejtterapia Kozpont Kft. | Unknown | No outcome recorded |
| — | NCT03107169 Comparator | Feb → Sep 2015 | Clostridium difficile colitis | Autonomous University of Nuevo León | Completed | No outcome recorded |
| — | NCT02570477 Comparator | Jan 2015 → Jan 2018 | Clostridium difficile colitis | Chinese University of Hong Kong | Unknown | No outcome recorded |
| — | NCT02210169 Comparator | Sep 2014 → Apr 2018 | bacterial infectious disease, infectious disease with sepsis | Murdoch Childrens Research Institute | Completed | No outcome recorded |
| — | NCT02088970 Background | Sep 2014 → Apr 2017 | fungal keratitis | Nantes University Hospital | Terminated | No outcome recorded |
| — | NCT01828892 Background | Mar 2014 → Jun 2017 | intestinal fistula | Jinling Hospital, China | Unknown | No outcome recorded |
| — | NCT01942447 Comparator | Oct 2013 → Dec 2014 | Clostridium difficile colitis | University Hospital Tuebingen | Unknown | No outcome recorded |
| — | NCT02787057 Background | Nov 2012 → Apr 2016 | infectious peritonitis | Peking University First Hospital | Completed | No outcome recorded |
| — | NCT01372371 Comparator | Jun 2011 → Jun 2012 | infectious disease | Ganga Hospital | Unknown | No outcome recorded |
| — | NCT01162733 Comparator | Jul 2010 → Jun 2012 | infectious disease | Christiana Care Health Services | Completed | No outcome recorded |
| — | NCT01037192 Comparator | Mar → Sep 2010 | — | Fraser Health | Completed | No outcome recorded |
| — | NCT01198509 Comparator | Jan 2010 → Jan 2013 | periodontal disorder, psoriatic arthritis | NYU Langone Health | Completed | No outcome recorded |
| — | NCT01918813 Background | Nov 2009 → Oct 2011 | hepatobiliary disorder, inflammatory bowel disease, pancreas disorder | Chikara Tashiro | Completed | No outcome recorded |
| — | NCT02027532 Comparator | Oct 2009 → Jun 2015 | infectious disease | University of Tennessee | Terminated | No outcome recorded |
| — | NCT00861887 Comparator | Feb → Nov 2009 | Clostridium difficile colitis | Corewell Health East | Withdrawn | No outcome recorded |
| — | NCT00818766 Comparator | Mar 2008 → Apr 2011 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT00451373 Background | Jul 2006 → Dec 2012 | acute kidney injury, infectious disease with sepsis | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT00296049 Comparator | Jul 2005 → Mar 2006 | bacterial infectious disease, childhood malignant neoplasm, neutropenia | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
Evidence & citations 36 cited values
Every value below carries the sentence it was read from. 445 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vancomycin | “The investigators want to compare whether Methicillin-resistant Staphylococcus Aureaus (MRSA) antibiotic prophylaxis with Cefazolin plus Daptomycin is superior to Cefazolin...” NCT01612052 ↗437“Participants ages 12-17 years old received IV vancomycin or semi-synthetic penicillin or first-generation cephalosporins or clindamycin, given as per local guidelines or...” NCT01728376 ↗ “Calcium sulfate beads will be loaded with best available antibiotics based on surgeon/infectious disease specialist determination from the following options (vancomycin,...” NCT07072923 ↗ “In the intervention arm, participants with airway microbiome positive for VAP pathogens will receive inhaled tobramycin, participants with airway S. aureus will receive inhaled...” NCT07463339 ↗ “Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through...” NCT00596167 ↗ “This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin,...” NCT02168816 ↗ “Some commonly used antibiotics for the treatment of PD peritonitis with their suggested concentrations in the antibiotic-lock are quoted as below: Cefazolin 10mg/mL...” NCT05971537 ↗ “'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin;...” NCT00634166 ↗ “Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the...” NCT03176134 ↗ “systemic bioavailability of vancomycin in healthy volunteers following single dose pulmonary administration of 16 mg, 32 mg, and 80 mg doses of AeroVanc in comparison with a...” NCT01537666 ↗ “Initial antimicrobial therapy for both groups consisted of fortified vancomycin eye drops 50 mg/ml, fortified ceftazidime eye drops 50 mg/ml hourly, and the antifungal agent...” NCT06967376 ↗ “ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin...” NCT03182907 ↗ “Patients were randomly assigned (1:1:1) to receive 10 days of treatment with one of two dose regimens of CRS3123 (200 mg and 400 mg orally twice daily) or oral vancomycin (125...” PMID 41581516 ↗ Jan 2026 “Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1000mg of Vancomycin powder AND a dose of 1200mg of...” NCT04597008 ↗ “Protocol for Expanded Access to Cyclic Irrigation of Vancomycin Hydrochloride and Tobramycin Sulfate in Patients Undergoing Exchange Arthroplasty for Periprosthetic Joint...” NCT06383611 ↗ “Patients with penicillin allergies, a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, or known MRSA colonization will receive vancomycin (2 grams)...” NCT06814223 ↗ “SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV...” NCT01513239 ↗ “The antibiotic bead pouch provides an antibiotic delivery mechanism. It is made by combining polymethyl methacrylate (PMMA) cement with generic forms of vancomycin and...” NCT05615844 ↗ “Drug stop within 24 hours after randomization:Piperacillin-tazobactam, amikacin, meropenem, cefepime, ceftazidime, vancomycin, teicoplanin, ciprofloxacin, levofloxacine and...” NCT07590648 ↗ “They will undergo an open label oral food challenge (OFC) to determine their threshold tolerated dose, after which they will start a week of antibiotics (Vancomycin and Neomycin).” NCT05695261 ↗ “Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.” NCT02276482 ↗ “temporary articular spacers printed in PLA (polylactic acid) impregnated with vancomycin in patients with periprosthetic infections of the hip, knee, or shoulder.” NCT07031999 ↗ “Eligible participants will receive preoperative intraosseous vancomycin (500 mg in 100 mL saline) as part of standard perioperative infection prophylaxis.” NCT07633418 ↗ “Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)” NCT01731236 ↗ “Seven-day local antibiotic irrigation (alternating vancomycin hydrochloride and tobramycin sulfate) via the temporary VT-X7 Knee or Hip Spacer.” NCT05607030 ↗ “Vancomycin is a glycopeptide antibiotic that is active against staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA).” NCT03439124 ↗ “The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole” NCT03303677 ↗ “The recommended SOC agents were IV vancomycin, IV clindamycin, and IV semisynthetic penicillins every 24 hours for up to 14 days.” NCT00711802 ↗ “triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.” NCT02515045 ↗ “The antibiotic regimen will consist of: oral vancomycin 250 mg qid, ciprofloxacin 500 mg bid, and metronidazole 500 mg tid.” NCT04238091 ↗ “Antibiotics for Clostridioides infection (oral vancomycin) or association of intravenous metronidazol for severe cases.” NCT06107569 ↗ “Vancomycin: 15 mg/kg/12h i.v (with determination of trough plasma levels on day 2-3 of treatment if available).” NCT05394298 ↗ “Dosage of Vancomycin decided by a serum trough concentration model, instead of decided by attending physician” NCT04088305 ↗ “one such compound includes triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin (TriMoxiVanc).” NCT02819908 ↗ “The antibiotics used in the study are benzylpenicillin, cloxacillin, piperacillin-tazobactam and vancomycin.” NCT07575009 ↗ “Vancomycin 1g IV every 12 h or Clindamycin 600-900g IV every 8h taking antibiotic sensitivity into account.” NCT07107477 ↗ “broad-spectrum prophylaxis of a combined single-shot of vancomycin 1 g and gentamicin 5 mg/kg parenterally” PMID 38243311 ↗ Jan 2024 “Step 1: Vancomycin 125 mg orally every 6 hours and metronidazole 250 mg orally every 6 hours for 5 days.” NCT05829109 ↗ “Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.” NCT01628666 ↗ “meropenem, oritavancin, oxacillin, penicillin, piperacillin-tazobactam, tigecycline, vancomycin” NCT05977868 ↗ “Participant given one of the following IV therapies: daptomycin, vancomycin, or ceftaroline.” NCT07148960 ↗ “Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin” NCT01613092 ↗ “The PMMA of the REMEDY SPECTRUM IM Spacer Nail is laden with gentamicin and vancomycin.” NCT06428448 ↗ “Provider choice of topical antibiotics includes Mupirocin 0.4mg/ml, Vancomycin 1mg/ml” NCT03935828 ↗ “PRP (nafcillin or flucloxacillin) or vancomycin, plus aztreonam or ciprofloxacin” NCT00303589 ↗ “broad spectrum antibiotics (vancomycin, ciprofloxacin, metronidazole) for 7 days” NCT03051698 ↗ “Ciprofloxacin, metronidazole, vancomycin, amoxicillin clavulanate or rifaximin.” NCT06443502 ↗ “10 day treatment with Vancomycin in adult subjects with Parkinson's disease” NCT06647277 ↗ “In case of methicillin resistance, vancomycin 1 g x 2 iv for 6 weeks.” NCT00423982 ↗ “Vancomycin or daptomycin, per discretion of the treating physician” NCT07376889 ↗ “antibiotic powder (Vancomycin 2gm) and 560mg gentamicin liquid.” NCT05421741 ↗ “Cefazolin (vancomycin in the case of allergy to cefazolin)” NCT02413034 ↗ “Vancomycin IV injection 1gm divided 250mg every 6hours” NCT06084754 ↗ “vancomycin: 125mg po, tid, D-6 to D-3” NCT05576961 ↗ “PO Vancomycin 250mgX4/d for 3 weeks” NCT02033408 ↗ “vancomycin for 15mg/kg,2 times/d” NCT02191475 ↗ “2 grams Vancomycin powder” NCT05084378 ↗ “Co-amoxiclav, vancomycin” NCT04048304 ↗ “* Vancomycin + Fortum” NCT02088970 ↗ “Ancef or Vancomycin” NCT01458223 ↗ “oral vancomycin” NCT01241552 ↗ “Vancomycin*” NCT02099240 ↗ “Vancomycin” NCT03928522 ↗ “Vancomycin” NCT04088305 ↗ |
| Known as | Firvanq | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Firvanq kit | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Novaplus | “Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)” NCT01731236 ↗ |
| Known as | NSC-757377 | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Oral vancomycin | “Oral vancomycin is an antibiotic that is commonly used to treat CDI.” NCT04241744 ↗ |
| Known as | PremierPro Rx | “Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)” NCT01731236 ↗ |
| Known as | Pulvules | “Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)” NCT01731236 ↗ |
| Known as | U-VANCO | “with U-VANCO (vancomycin hydrochloride)” NCT03883022 ↗ |
| Known as | VAN | “linezolid (LZD) therapy with that of vancomycin (VAN) therapy” PMID 18719064 ↗ Aug 20081“Vancomycin (VAN) treatment” NCT07659886 ↗ |
| Known as | Vancocin | “Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)” NCT01731236 ↗ |
| Known as | Vancocin (vancomycin) | “Vancocin (vancomycin)” NCT00596167 ↗ |
| Known as | Vancocin HCl | “Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)” NCT01731236 ↗ |
| Known as | Vancocin hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Vancocin i.v. | “Patients randomized into the treatment arm will receive 1-2 g of vancomycin powder (Vancocin® i.v.) which will be administered above the closed muscle fascia (suprafascially)...” NCT04017468 ↗ |
| Known as | Vancocin matrigel | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Vancogel(R) | “Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R)” NCT00945152 ↗ |
| Known as | Vancoled | “Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)” NCT01731236 ↗ |
| Known as | Vancomicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Vancomycin "Hospira" | “vancomycin 500 mg (Vancomycin "Hospira"), powder for concentrate” NCT03157388 ↗ |
| Known as | Vancomycin (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | vancomycin (China Chemical & Pharmaceutical Co., Ltd. (CCPC / Taiwan)) | “vancomycin® (China Chemical & Pharmaceutical Co., Ltd. (CCPC / Taiwan))” NCT04500275 ↗ |
| Known as | Vancomycin (Vancocin) | “Vancomycin (Vancocin)” NCT00818766 ↗ |
| Known as | Vancomycin HCl | “Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)” NCT01731236 ↗1“Drug: Vancomycin HCL” NCT01623817 ↗ |
| Known as | Vancomycin HCL: Brand name Vancocin | “Vancomycin HCL: Brand name Vancocin” NCT01619982 ↗ |
| Known as | vancomycin hydrochloride | “Protocol for Expanded Access to Cyclic Irrigation of Vancomycin Hydrochloride and Tobramycin Sulfate in Patients Undergoing Exchange Arthroplasty for Periprosthetic Joint...” NCT06383611 ↗8“Intervention: Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride 15 mg/kg body weight” NCT01619982 ↗ “Vancomycin hydrochloride dry powder for inhalation” NCT01537666 ↗ “with U-VANCO (vancomycin hydrochloride)” NCT03883022 ↗ “Drug: Vancomycin Hydrochloride” NCT04500275 ↗ |
| Known as | Vancomycin monohydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Vancomycin-Vanco-Teva | “Vancomycin-Vanco-Teva®” NCT02033408 ↗ |
| Known as | vancomycin: vancomicina sala 500 mg vial. | “vancomycin: vancomicina sala 500 mg vial.” NCT01592032 ↗ |
| Known as | Vancomycine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05651464 ↗ |
| Known as | Vancor | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Vancozin 250 mg capsule | “Intervention: vancomycin 500 mg tid for 7 days (Vancozin 250 mg capsule)” NCT03403972 ↗ |
| Known as | Vanoled | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Action | Inhibit | “inhibits bacterial growth by hindering the synthesis of cell wall in bacteria” NCT02443064 ↗ |
| Modality | Other / unclassified | “Vancomycin is a glycopeptide antibiotic” NCT01509339 ↗ |
| Route | Intravenous | “Vancomycin IV is administered over at least 1 hour twice daily.” NCT00003805 ↗ |